Correll, Christoph U.
Benson, Carmela
Emond, Bruno
Patel, Charmi
Lafeuille, Marie-Hélène
Lin, Dee http://orcid.org/0000-0003-2565-7984
Morrison, Laura
Ghelerter, Isabelle
Lefebvre, Patrick
Mavros, Panagiotis
Article History
Received: 23 June 2022
Accepted: 26 January 2023
First Online: 11 February 2023
Competing interests
: B.E., M.H.L., L.M., I.G., and P.L. are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Janssen Scientific Affairs, LLC, which funded the development and conduct of this study and manuscript. C.B., C.P., D.L., and P.M. are employees of Janssen Scientific Affairs, LLC and stockholders of Johnson & Johnson. C.U.C. has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Axsome, Cardio Diagnostics, Compass, Damitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Pharmabrain, Recordati, Relmada, Reviva, Rovi, Seqirus, Servier, SK Life Science, Sumitomo Dainippon, Sunovion, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Relmada, Reviva, Rovi, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Mindpax, and LB Pharma.